Ilyang Pharmaceutical Co Ltd (007575) — Cash Flow-to-Debt Ratio
Ilyang Pharmaceutical Co Ltd (007575) has a Cash Flow-to-Debt Ratio of 0.01x as of June 2025, meaning its operating cash flow of ₩2.26 Billion could theoretically repay 0% of its total liabilities (₩205.41 Billion) in one year. See cash generation quality of Ilyang Pharmaceutical Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Ilyang Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Ilyang Pharmaceutical Co Ltd across 11 annual periods. Also explore how fast is Ilyang Pharmaceutical Co Ltd growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Ilyang Pharmaceutical Co Ltd (2014–2024)
Year-by-year debt coverage analysis for Ilyang Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see how much is Ilyang Pharmaceutical Co Ltd worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.03x | ₩5.61 Billion | ₩189.63 Billion | ▼ -67.5% |
| 2023 | 0.09x | ₩14.62 Billion | ₩160.25 Billion | ▼ -37.1% |
| 2022 | 0.15x | ₩29.94 Billion | ₩206.33 Billion | ▼ -51.8% |
| 2021 | 0.30x | ₩67.02 Billion | ₩222.51 Billion | ▲ +1.8% |
| 2020 | 0.30x | ₩57.48 Billion | ₩194.19 Billion | ▲ +75.6% |
| 2019 | 0.17x | ₩36.19 Billion | ₩214.72 Billion | ▲ +69.5% |
| 2018 | 0.10x | ₩22.12 Billion | ₩222.37 Billion | ▼ -25.3% |
| 2017 | 0.13x | ₩30.03 Billion | ₩225.39 Billion | ▲ +5.6% |
| 2016 | 0.13x | ₩26.98 Billion | ₩213.91 Billion | ▼ -30.9% |
| 2015 | 0.18x | ₩40.27 Billion | ₩220.62 Billion | ▲ +142.4% |
| 2014 | 0.08x | ₩18.63 Billion | ₩247.37 Billion | — |